Refine my results

Oligoprogression : Eine innovative Indikation für die Körperstereotaxie bei metastasierten Tumorsituationen = Oligoprogression : An innovative indication for stereotactic body radiotherapy in the metastatic setting

Guckenberger, Matthias

In: Strahlentherapie und Onkologie, 2015, vol. 191, no. 5, p. 453-455

Palliative Care – Möglichkeiten und Grenzen aus sozialethischer Sicht

Zimmermann-Acklin, Markus

In: Seelsorge in Palliative Care, 2012, p. 61-73

Systematic analysis of synergistic proteome modulations in a drug combination of cisplatin and MLN4924

Megger, Dominik Andre ; Abou-Eid, Shadi ; Zülch, Birgit ; Sitek, Barbara

In: Molecular Omics, 2018, vol. 14, no. 6, p. 450–457

Chemotherapeutic treatment regimens often take advantage of synergistic effects of drug combinations. Anticipating that synergistic effects on the cell biological level likely manifest on the proteome level, the analysis of proteome modulations represents an appropriate strategy to study drug combinations on a molecular level. More specifically, the detection of single proteins exhibiting...

Möglichkeiten der systemischen Therapie in metastasierten Stadien des Magenkarzinoms = Treatment options for chemotherapy in metastatic gastric cancer

Wagner, A.D. ; Stahl, M.

Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer : Treatment outcome outside clinical trials = Simultane neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin beim lokal fortgeschrittenen Rektumkarzinom : Therapieergebnisse außerhalb klinischer Studien

Winkler, J. ; Zipp, L. ; Knoblich, J. ; Zimmermann, F.

In: Strahlentherapie und Onkologie, 2012, vol. 188, no. 5, p. 377-382

Docetaxel-based chemotherapy in the treatment of gastric cancer

Roth, A. D. ; Ajani, J.

In: Annals of Oncology, 2003, vol. 14, p. ii41-ii44

Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites

Fedier, A. ; Schlamminger, M. ; Schwarz, V. A. ; Haller, U. ; Howell, S. B. ; Fink, D.

In: Annals of Oncology, 2003, vol. 14, no. 6, p. 938-945

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK

Borner, M. ; Koeberle, D. ; Von Moos, R. ; Saletti, P. ; Rauch, D. ; Hess, V. ; Trojan, A. ; Helbling, D. ; Pestalozzi, B. ; Caspar, C. ; Ruhstaller, T. ; Roth, A. ; Kappeler, A. ; Dietrich, D. ; Lanz, D. ; Mingrone, W.

In: Annals of Oncology, 2008, vol. 19, no. 7, p. 1288-1292

Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial

Hess, V. ; Pratsch, S. ; Potthast, S. ; Lee, L. ; Winterhalder, R. ; Widmer, L. ; Cescato, C. ; Lohri, A. ; Jost, L. ; Stillhart, P. ; Pestalozzi, B. ; Herrmann, R.

In: Annals of Oncology, 2010, vol. 21, no. 12, p. 2390-2395

5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)-cisplatin in advanced gastric carcinoma: a phase I-II trial

Roth, A. D. ; Maibach, R. ; Fazio, N. ; Sessa, C. ; Stupp, R. ; Morant, R. ; Herrmann, R. ; Borner, M. M. ; Goldhirsch, A. ; de Braud, F.

In: Annals of Oncology, 2004, vol. 15, no. 5, p. 759-764